MNKD Stock Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.79|
|52 Week High||US$6.25|
|52 Week Low||US$3.12|
|1 Month Change||-14.06%|
|3 Month Change||-18.32%|
|1 Year Change||7.06%|
|3 Year Change||193.80%|
|5 Year Change||13.32%|
|Change since IPO||-94.62%|
Recent News & Updates
|MNKD||US Biotechs||US Market|
Return vs Industry: MNKD exceeded the US Biotechs industry which returned -20% over the past year.
Return vs Market: MNKD matched the US Market which returned 6.6% over the past year.
|MNKD Average Weekly Movement||6.6%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: MNKD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: MNKD's weekly volatility (7%) has been stable over the past year.
About the Company
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism.
MannKind Fundamentals Summary
|MNKD fundamental statistics|
Is MNKD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MNKD income statement (TTM)|
|Cost of Revenue||US$33.71m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.32|
|Net Profit Margin||-97.43%|
How did MNKD perform over the long term?See historical performance and comparison
Is MannKind undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether MannKind is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MannKind has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is MannKind forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MNKD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: MNKD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MNKD's is expected to become profitable in the next 3 years.
Revenue vs Market: MNKD's revenue (31.8% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: MNKD's revenue (31.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MNKD's Return on Equity is forecast to be high in 3 years time
How has MannKind performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MNKD is currently unprofitable.
Growing Profit Margin: MNKD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MNKD is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare MNKD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MNKD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: MNKD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is MannKind's financial position?
Financial Position Analysis
Short Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: MNKD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: MNKD has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: MNKD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MNKD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MNKD has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 9.1% each year.
What is MannKind current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MNKD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MNKD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MNKD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MNKD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MNKD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Castagna (44 yo)
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD3.56M) is above average for companies of similar size in the US market ($USD2.38M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
Experienced Management: MNKD's management team is considered experienced (4.6 years average tenure).
Experienced Board: MNKD's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8%.
MannKind Corporation's employee growth, exchange listings and data sources
- Name: MannKind Corporation
- Ticker: MNKD
- Exchange: NasdaqGM
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$952.262m
- Shares outstanding: 251.26m
- Website: https://www.mannkindcorp.com
Number of Employees
- MannKind Corporation
- 30930 Russell Ranch Road
- Suite 300
- Westlake Village
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 23:46|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.